Lifestyle modification program
Studies of lifestyle modification program in people
35 studies gave lifestyle modification program to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases PhenoAge-4.9 vs +1.3 years; between-group p < 0.001 down: Decreases body weight-5.7 kg between-group no change: Has no effect on GDF-15 | Randomized trial6 months | 181 peopleBothmean 50.8 ± 10.9 yearsMidlife adults; Patient cohorts | Frontiers in aging, Sep 10, 2026 |
up: Improves dietary adherencer = 0.65, p = 0.006 down: Decreases perceived stressr = 0.58, p = 0.013 up: Improves quality of lifer = 0.55, p = 0.018 | Trial16 weeks | 18 peopleBothmedian age 47 yearsMidlife adults | Academic Journal of Health Sciences, Aug 26, 2026 |
up: Improves Physical Performance Testmean difference 2.5 points, 95% CI 1.2-3.8 | Randomized trial6 months | 114 peopleBoth65-85 yearsOlder adults; Patient cohorts | The lancet. Healthy longevity, Jul 30, 2026 |
down: Decreases body mass index up: Improves physical function up: Improves health-related quality of life | Randomized trialthree months | 200 peopleWomen50-58 yearsMidlife adults; Postmenopausal women | Electronic Journal of General Medicine, Jun 1, 2026 |
| Randomized trial6 months | 120 peopleWomen40–42 yearsMidlife adults; perimenopausal women | International Journal of Drug Delivery Technology, Apr 11, 2026 | |
down: Lowers the risk of type 2 diabetes down: Decreases fasting blood glucose down: Decreases BMI | Randomized trial18-month | 320 peoplewomenWomen with a history of GDM in rural areas of Hunan province | BMC public health, Mar 14, 2026 |
down: Decreases HbA1c7.9% (7.0-8.7) vs 8.6% (7.6-9.8), p<0.001 | Randomized trial3 months | 353 peopleType 2 diabetes | medRxiv, Mar 9, 2026 |
up: Improves healthy behavior73.8% compared to 26.2%, p < 0.001 no change: Has no effect on glycemic controlp = 0.061 | Randomized trial22 weeks | Type-2 Diabetes Mellitus | Research Square, Mar 2, 2026 |
up: Improves visual evoked potential down: Decreases retinal nerve fiber layer thickening no change: Has no effect on central macula thickness | Trial12 weeks | 75 peopleType 2 diabetes mellitus with diabetic retinopathy | The Journal of the Association of Physicians of India, Mar 1, 2026 |
up: Improves diet qualityOR = 4.7, 95% CI = 1.2–17.8 | Randomized trial3 months | 220 peopleBothmean age 48 ± 10 yearsMidlife adults; precontemplation/contemplation stage in adults at high risk for diabetes | Research Square, Feb 27, 2026 |
down: Decreases body mass index down: Decreases muscle massminimal loss | Trialsix follow-up visits | 44 peopleHospitalized psychiatric patients treated with antipsychotic and/or antidepressant drugs | Mediterranean Journal of Nutrition and Metabolism, Feb 24, 2026 |
down: Decreases MFN2 degradation products down: Decreases body mass index | Trial12 months | 43 peopleBotholder adultsOlder adults; in metabolically unhealthy obesity after 12 months | Nutrients, Feb 1, 2026 |
| Trial8 months | 39 peoplePatient cohorts | Research Square, Jan 16, 2026 | |
down: Decreases cardiovascular risk8.03% to 6.71% down: Decreases body weight73.1 to 71.7 kg down: Decreases physical inactivity60% to 39% | Trial16-week | 100 peopleBothGeneral population | Journal of clinical medicine, Jan 13, 2026 |
up: Increases prediabetes remission45.9 % vs 6.3 %; RR 7.04, 95 % CI 5.12-10.06 down: Decreases fasting plasma glucose-5.2 mg/dL down: Decreases body weight-3.7 kg | Randomized trial12 months | 1,092 peopleWomen30-60 yearsMidlife adults; isolated impaired fasting glucose | Diabetes research and clinical practice, Jan 13, 2026 |
up: Improves DAS28-CRPmean change -1.0 ± SD 0.9 up: Improves metabolic syndrome Z-scoremean change -1.6 ± SD 2.4 | Trial1.9 ± 0.5 years | 14 people78.6% were women68.9 ± 5.0 years oldAdults with obesity and rheumatoid arthritis | ACR open rheumatology, Dec 1, 2025 |
up: Improves handgrip strength down: Decreases HbA1c | Randomized trial12-week | 31 peopleMost participants were femalemidlifeHealthy adults born between 1955 and 1963 who are part of the Korean baby boomer generation | Nutrients, Sep 20, 2025 |
up: Improves hand grip strengthP = 0.039 up: Improves quality of lifeP = 0.019 up: Improves social participationP = 0.026 | Randomized trial12-mo | 93 peopleMenolder adultsOlder adults; normal weight group | Nutrition (Burbank, Los Angeles County, Calif.), Jun 13, 2025 |
up: Improves physical function+25.5 m, 95%CI (3.2–47.9) up: Improves knee extension strength+19 N, 95%CI (1–38) up: Increases dietary protein intake+15 g/day, 95%CI (1–28) | Randomized trialsix-month period | 65 peoplepredominantly female (91%)mean age of 65 years (SD = 7)Non-Western migrant backgrounds, aged 55 years or older | The journal of nutrition, health & aging, May 22, 2025 |
down: Decreases metabolic syndrome down: Decreases blood glucose down: Decreases blood pressure | Trial10 days | 95 people85 women out of 95 participants18-70 yearsVolunteers | Journal of lifestyle medicine, Feb 28, 2025 |
down: Decreases systolic blood pressuremedian from 173.86 mmHg to 142.53 mmHg no change: Has no effect on diastolic blood pressure | Trial | 106 peopleMidlife adults; Older adults; Patient cohorts | African journal of reproductive health, Oct 31, 2024 |
no change: Has no effect on distal symmetrical polyneuropathyILS 21.5%, metformin 21.5%, placebo 21.9% down: Lowers the risk of distal symmetrical polyneuropathy17.4% (95% CI 3.0, 29.3) lower OR | Randomized trialapproximately 21 years after DPP randomization | 3,234 people≥25 years oldMidlife adults; Older adults; at high risk for diabetes | Diabetes care, Mar 19, 2024 |
| Review of trialsmedian study duration for all studies was 6 months, with the shortest intervention period lasting 2 h (0.00274 months) and the longest intervention lasting 10 years (120 months) | minimum age of 60 yearsParticipants in U.S.-based lifestyle clinical trials for cognitive health | Contemporary clinical trials communications, Feb 15, 2024 | |
down: Decreases body weight-3.7 ± 4 kg, P < 0.001 up: Increases telomere length+0.25 ± 0.9 vs -0.07 ± 1.0 relative units, p = 0.036 down: Lowers the risk of telomere shorteningOR = 0.17, 95%CI: 0.05-0.64, p = 0.008 | Randomized trial3 years | 317 peopleWomenmean age, 65.8 ± 4.98 yearsOlder adults; Patient cohorts | Clinical nutrition (Edinburgh, Scotland), Jul 10, 2023 |
no change: Has no effect on body weight-0.17%, 95% CI -1.04, 0.71 down: Decreases HbA1cmean difference = -0.24%, Hedges' g = 0.23 | Randomized trialapproximately 7 to 9 months | 494 peopleBothmean age of 68 yearsOverweight or obese community club members | PLoS medicine, Apr 15, 2022 |
| Trial13-month | 298 peopleBothaverage 68.0 years oldAdults aged 60–75 with overweight or obesity | Journal of applied gerontology : the official journal of the Southern Gerontological Society, Feb 2, 2022 | |
down: Decreases fat mass | Trial12 months | 158 people36 men (22.8%) and 122 (77.2%) women72.21 ± 5.04 yearsMetabolically healthy elderly population with overweight/obesity | International journal of environmental research and public health, Nov 13, 2021 |
up: Increases physical activity down: Decreases anxiety symptoms up: Improves daily functioning | Randomized trial10 weeks | 21 peoplePatients seen by the geriatricians in primary care and the behavioral neurology service at Mayo Clinic Arizona who expressed cognitive concerns but had no evidence of objective cognitive decline | Brain sciences, Sep 30, 2021 |
down: Decreases body weight up: Improves muscle strength down: Decreases dietary fat intake | Trial6 months | Both57-74 yearsMidlife adults; Older adults; inactive adults with obesity and elevated cardiovascular disease risk | PloS one, Aug 25, 2021 |
| Trial1 year | 111 peoplemean age, 82.37 yearsOlder adults; The oldest old; institutionalized older adults with and without dementia | International journal of environmental research and public health, Jul 17, 2021 | |
down: Decreases body weight3.22 ± 3.43 kg vs 0.03 ± 2.51 kg; 41.1% achieved 5% weight loss down: Decreases cardiometabolic risk factors | Randomized trial24 months | 480 peopleBotholder adultsOlder adults; obese older adults, versus usual care | Experimental gerontology, Oct 20, 2019 |
down: Lowers the risk of slow gait speedadjusted OR 0.84 [0.71 to 0.99] up: Improves gait speedadjusted mean difference [95% CI]: 0.019 [0.007 to 0.031] m/s, p = .002 up: Improves physical function0.037 [0.011 to 0.063], p = .005 | Randomized trialapproximately 11 years postrandomization and 1.5 years after the intervention was stopped | 3,783 peopleaged 45-76 years at enrollmentMidlife adults; Older adults; type 2 diabetes, overweight and obese | The journals of gerontology. Series A, Biological sciences and medical sciences, Oct 21, 2017 |
down: Decreases malondialdehyde5.28±0.52 vs 4.48±0.69 m mol/ml down: Decreases systolic blood pressure down: Decreases fasting lipids | Trialthree months | 74 peopleBoth60 to 80 yearsOlder adults | Journal of clinical and diagnostic research : JCDR, Sep 1, 2016 |
down: Decreases body weight down: Decreases LDL cholesterol up: Increases adiponectin | Trial8 weeks | Women8-week program in obese female college students | Advances in experimental medicine and biology, Jan 1, 2013 |
down: Decreases type 2 diabetes incidence58% reduction (95% CI 48 to 66%) versus placebo | Randomized trialaverage follow-up 2.8 years | 3,234 peopleBothmean 51 yearsMidlife adults | The New England journal of medicine, Feb 7, 2002 |